<DOC>
	<DOCNO>NCT02252978</DOCNO>
	<brief_summary>This phase II trial study ciprofloxacin compare inactive treatment ( placebo ) diagnose prostate cancer patient undergo removal prostate cell tissue examination ( biopsy ) . Ciprofloxacin antibiotic , type drug use treat infection cause bacteria . Giving ciprofloxacin patient undergo prostate biopsy may help low abnormal prostate-specific antigen ( PSA ) level cause bacterial infection prostate gland may may affect detection rate prostate cancer .</brief_summary>
	<brief_title>Ciprofloxacin Compared Placebo Diagnosing Prostate Cancer Patients Undergoing Prostate Biopsy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine non-inferiority rate detection prostate cancer men decrease serum PSA value treat placebo compare ciprofloxacin prior prostate biopsy . SECONDARY OBJECTIVES : I . To compare change PSA randomization biopsy men treat ciprofloxacin versus treat placebo . II . To compare rate post-biopsy complication ( include duration hematuria , hematochezia , hematospermia , fever &gt; 101Â°F , hospital admission rate related biopsy , sepsis , pain ) men treat ciprofloxacin versus treat placebo . TERTIARY OBJECTIVES : I . To determine benign prostatic hyperplasia ( BPH ) erectile dysfunction associate abnormal PSA prostatic inflammation report biopsy specimen . II . To determine correlation change PSA randomization biopsy urinalysis pre- post-ciprofloxacin versus placebo . III . To determine correlation change PSA prostate massage pre- post-ciprofloxacin versus placebo . IV . To determine qualitative quantitative difference flora ( ciprofloxacin resistant organism ) obtain rectal swab pre- post- two week course ciprofloxacin vs. placebo . V. To correlate prostate symptom severity ( International Prostate Symptom Score [ IPSS ] ) erectile function ( International Index Erectile Function [ IIEF-5 ] ) baseline . VI . To correlate urinary , prostate massage rectal swab finding pathology finding include cancer , inflammation , prostatic intra-epithelial neoplasia ( PIN ) , atypical acinar proliferation ( ASAP ) finding end study . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive ciprofloxacin orally ( PO ) twice daily ( BID ) 2 week . ARM II : Patients receive ciprofloxacin PO BID 2 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Abnormal serum PSA ( total &gt; 2.5 ng/ml clinically important biomarker parameter , include PSA velocity density ) associate without normal digital rectal examination Men elect proceed diagnostic prostate biopsy Any prostate size Willingness ability give inform consent History prostate cancer Urine culture positive significant urinary tract infection ( UTI ) A history antibiotic use within one month prior initial PSA level measurement Allergy fluoroquinolones Currently take imperative medication significant drugdrug interaction ciprofloxacin Compromised renal function estimate glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73m^2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>